Prostate cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PSMA 273
• AR 16
• TP53 2
• PARP 13
• PTEN 4
• AKT 1
• BRCA2 7
• BRCA1 9
• STAT3 0
• PI3K 2
• PD-L1 6
• mTOR 1
• PD-1 13
• EZH2 7
• MYC 1
• B7-H3 8
• EGFR 2
• CTNNB1 1
• JNK 0
• ERK 0
• HIF-1 0
• VEGF 2
• BCL-2 0
• MAPK 0
• AMPK 0
• CDK4/6 4
• HER2 6
• NRF2 0
• FAK 0
• PPAR 0
• YAP 0
• IL-6 0
• STING 0
• COX-2 0
• CTLA-4 0
• DLL3 6
• GLP-1 1
• GPX4 0
• HSP90 0
• ATM 1
• HDAC 0
• IL-15 4
• METTL3 1
• BRD4 0
• HER3 2
• JAK 1
• CXCR4 0
• TROP2 3
• CD47 1
• IGF1R 0
• IL-1 0
• MET 1
• PALB2 4
• RB1 0
• TNF 0
• APOE 0
• FGFR 1
• KRAS 0
• MDM2 0
• MEK 0

9 of 9+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• ALLCDC NCCDPHP · U48

  Optimal survey questions for prostate cancer screening and shared decision-making

  New York University School of Medicine· New York, United States· US$443,904 awarded in fiscal year 2025· until Sept 2029

• ALLCDC NCCDPHP · U48

  Developing and Evaluating Computable Phenotypes to Identify Active Surveillance in Prostate Cancer Using Electronic Health Record Data

  Univ of Massachusetts Med Sch Worcester· Worcester, United States· US$399,303 awarded in fiscal year 2025· until Sept 2028

• NIH NCI · R37

  Targeting Lactylation of Critical Drivers in Neuroendocrine Prostate Cancer for Therapy

  University of Kentucky· Lexington, United States· US$453,367 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R43

  De Novo Minibinder Radiotheranostics for Targeted Treatment of Prostate Cancer

  Vesto Therapeutics, Inc· Seattle, United States· US$400,000 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R42

  Dual Acting Bone Defenders for Inhibiting Cancer Mediated Bone Destruction

  Bonestrong Therapeutics Inc.· Portland, United States· US$400,000 awarded in fiscal year 2026· until Aug 2027

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting stress signaling pathways to enhance prostate cancer immunotherapy (IMMSTRESS)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €202,125· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Circulating Tumor Cell-informed RADioresponse Assessment from heme-axis signatuRes (CTC-RADAR)

  Koc University· Istanbul, Türkiye· EU contribution €398,612· until Dec 2029· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Greece· EU contribution €796,590· until Dec 2030· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Exploitation of bioorthogonal click-to-release chemistry for precision cancer therapy (click-to-cure)

  Kobenhavns Universitet· Kobenhavn, Denmark· EU contribution €247,553· until Dec 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Proteoform-Resolved Lateral Flow Immunoassay with Antibody Mimics and Engineered Release for Precise Prostate Cancer Diagnosis (PRIME)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €260,348· until Sept 2028

10 of 919 running projects, newest first. Listed amounts together: US$580.4m + €116.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Imaging of Solid Tumors Using DLL3 SPECT

  NCT07052760· Thomas Hope· Updated 29 Apr 2026

  “Sponsor funding”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate

  NCT06941480· Memorial Sloan Kettering Cancer Center· Source

• A Study of Tarlatamab for People With Prostate Cancer

  NCT07111507· Memorial Sloan Kettering Cancer Center· Source

• Imaging of Solid Tumors Using DLL3 SPECT

  NCT07052760· Thomas Hope· Source

• A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

  NCT04471727· Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 42
• Organoids 15
• Mendelian Randomization Analysis 39
• CRISPR-Cas Systems 15
• Gene Expression Profiling 154
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 9
• Exome Sequencing 4
• Proteomics 47
• Metabolomics 27
• Mass Spectrometry 16
• Flow Cytometry 58
• Immunohistochemistry 120
• Liquid Biopsy 30
• Circulating Tumor DNA 32
• Xenograft Model Antitumor Assays 287
• Positron-Emission Tomography 125
• Magnetic Resonance Imaging 465
• Machine Learning 122
• Deep Learning 101
• Cohort Studies 276
• Genome-Wide Association Study 62

• Circulating Tumor DNA in Oligoprogressive Prostate Cancer Treated With Stereotactic Radiotherapy: A Prespecified Secondary Analysis of a Nonrandomized Clinical Trial.

  JAMA Netw Open, Nov 2026

• Circulating tumour DNA and extrachromosomal DNA in prostate and bladder cancer: biology, clinical applications and future perspectives.

  World J Urol, Oct 2026

• Uncovering the diagnostic potential of seminal fluid beyond fertility: cfDNA methylation analysis for the detection of clinically significant prostate cancer.

  PLoS One, Sept 2026

• Prospective Evaluation of Circulating Tumor DNA in Metastatic Hormone-Sensitive Prostate Cancer.

  JCO Precis Oncol, Sept 2026

• Prognostic value of circulating tumor DNA and copy-number alterations in patients receiving tandem [225Ac]Ac-/[177Lu]Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer: a prospective observational study.

  BMC Cancer, Aug 2026

• Prognostic Value of Androgen Receptor (AR) Gene Alterations Detected in Circulating Tumor DNA (ctDNA) in Patients With Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis.

  Clin Genitourin Cancer, Aug 2026

• Immunoediting and precision biomarkers in prostate cancer: The emerging role of liquid biopsy, immune contexture and HLA genotype (Review).

  Int J Oncol, Jul 2026

• Evaluation of a Methylated Circulating Tumour DNA Panel for Detection and Disease Stratification in Prostate Cancer.

  Int J Mol Sci, Jul 2026

• Circulating Tumor DNA Genomic Profiling in 223Ra-Treated Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study.

  J Nucl Med, Jul 2026

• AR and Beyond: ctDNA Maps Resistance Evolution in mCRPC.

  Clin Cancer Res, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.